leadf
logo-loader
viewbit bio

Elpis BioMed applying its 'disruptive' technology to produce human cells at scale

Mark Kotter, founder of Elpis BioMed Ltd, tells Proactive the company was spun-out of Cambridge University and is built around technology which allows you to produce human cells at scale.

''These are very important in the context of drug discovery, biomedical research and also cell therapy''.

Its 'disruptive' technology is centred around 'cell reprogramming' - ''it's similar to rebooting a computer with a new programme ... if you do this then you get a new cell type'', Kotter says.

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of bit bio named herein, including the promotion by the Company of bit bio in any Content on the Site, the Company receives from said issuer...

FOR OUR FULL DISCLAIMER CLICK HERE

archTIS makes transformative move in acquiring Nucleus Cyber

archTIS (ASX: AR9) CEO Daniel Lai joins Steve Darling from Proactive to share details of a transformative acquisition with the company entering a binding term sheet to acquire global information protection business Nucleus Cyber. Lai discusses why this is a key move for the company...

1 day, 7 hours ago

2 min read